Ieq Capital LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Ieq Capital LLC acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 15,013 shares of the biopharmaceutical company's stock, valued at approximately $313,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. abrdn plc bought a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $10,115,000. Jane Street Group LLC grew its holdings in Catalyst Pharmaceuticals by 245.4% in the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company's stock worth $7,990,000 after purchasing an additional 285,564 shares during the period. Walleye Capital LLC bought a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $4,936,000. Pacer Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock valued at $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Catalyst Pharmaceuticals by 129.4% in the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company's stock worth $4,939,000 after purchasing an additional 140,129 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company's stock, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 11.00% of the company's stock.

Remove Ads

Analysts Set New Price Targets

CPRX has been the subject of a number of recent research reports. Bank of America reiterated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Truist Financial upped their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, November 11th. Stephens reissued an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday. Finally, Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $32.50.

Catalyst Pharmaceuticals Stock Down 2.6 %

NASDAQ:CPRX traded down $0.60 on Monday, hitting $22.30. The stock had a trading volume of 1,062,824 shares, compared to its average volume of 1,271,335. The business's 50-day simple moving average is $22.24 and its two-hundred day simple moving average is $21.45. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $24.64.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.